Kenneth Yu

22PUBLICATIONS
120CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyPredictive and prognostic markersCharacterisation of biological macromolecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Mar 27, 2026
POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer.

Wungki Park, Shigeaki Umeda, Marc Hilmi

|Jan 13, 2026
A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer.

Brinda Alagesan, Anna M Varghese, Celina Ang

|Sep 10, 2025
PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.

Jennifer J Knox, Grainne O'Kane, Daniel King

|Oct 26, 2024
Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort.

Fergus Keane, Catherine O'Connor, Drew Moss

|May 11, 2024
Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery.

Edward Christopher Dee, Victor C Ng, Eileen M O'Reilly

|Mar 19, 2023
Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma.

Kenneth H Yu, Paul Cockrum, Andy Surinach

Pageof 4

Frequent Collaborators

14 joint publications

Eileen M O'Reilly

5 joint publications

Wungki Park

5 joint publications

David P Kelsen

3 joint publications

Fiyinfolu Balogun